RxDoctor Payments Data

Athanasios Manole, MD

Interventional Pain Medicine · Albuquerque, NMNPI 1780002220

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,910 of the $8,790 with a category attached, or 78.6%. It is spread thinly across 30 manufacturers, the largest accounting for just 24.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,011, more than ten times the $39 reported in 2020.

$8,790in general payments, 2019–2025

Across 330 payments — averaging $26.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Zimmer Biomet$1K
  • Medtronic$1K
  • Nevro Corp.$1K
  • Abbott$500
  • Globus Medical$480
  • plus $2K from 24 others

What the payments were for

  • Travel & lodging$1,88021%
  • Food & beverage$6,91079%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few interventional pain medicine providers in New Mexicoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$835,160
Medicare patients
581
Services billed
28,916

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen483$9,294
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen268$8,759
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl47$8,084
Oxycodone Hcl313$6,660
Gabapentin499$6,148
Buprenorphine Hcl156$5,597
Naloxone Hcl66$4,283
Pregabalin194$4,182
Morphine Sulfate ErMorphine Sulfate42$2,639
Tizanidine Hcl339$2,328
Buprenorphine14$2,119
Baclofen92$2,083
Tramadol Hcl144$1,480
Duloxetine Hcl69$1,426
Butalb-Acetaminoph-Caff-CodeinButalbit/Acetamin/Caff/Codeine15$1,346

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →